Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2019 · 10-Q
Revenue$2.32K$2.32Kno prior Q2 2018 on file Net Income$3.73M$3.73Mno prior Q2 2018 on file EPS Diluted$0.07$0.07no prior Q2 2018 on file Operating Income-$896,047— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-38622.7%
Net margin160761.5%
ended Feb 28, 2019 · filed Apr 15, 2019 · 46 d after period end